11,479 Shares in Delcath Systems, Inc. (NASDAQ:DCTH) Bought by Barclays PLC

Barclays PLC bought a new position in shares of Delcath Systems, Inc. (NASDAQ:DCTH) in the 3rd quarter, HoldingsChannel reports. The institutional investor bought 11,479 shares of the company’s stock, valued at approximately $104,000.

Several other institutional investors have also recently made changes to their positions in DCTH. Renaissance Technologies LLC purchased a new position in shares of Delcath Systems during the second quarter worth $694,000. Marshall Wace LLP raised its holdings in shares of Delcath Systems by 7.0% during the second quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock worth $776,000 after purchasing an additional 6,066 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in Delcath Systems in the second quarter valued at $370,000. Shellback Capital LP purchased a new position in Delcath Systems in the second quarter valued at $1,353,000. Finally, Riverwater Partners LLC purchased a new position in Delcath Systems in the third quarter valued at $161,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on DCTH shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Delcath Systems in a report on Friday, October 18th. Stephens reissued a “buy” rating on shares of Delcath Systems in a research note on Friday, October 18th. StockNews.com raised shares of Delcath Systems from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of Delcath Systems in a research note on Monday, November 11th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.50.

Delcath Systems Price Performance

NASDAQ:DCTH opened at $12.06 on Thursday. The firm has a market capitalization of $385.61 million, a price-to-earnings ratio of -8.93 and a beta of 0.87. The company’s 50-day moving average is $11.21 and its two-hundred day moving average is $9.71. Delcath Systems, Inc. has a 1-year low of $3.70 and a 1-year high of $13.30.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.